Unmet Need in Essential Thrombocythemia and Polycythemia Vera

Ashwin Kishtagari; Aaron T Gerds

doi:10.1016/j.hoc.2021.01.003

Unmet Need in Essential Thrombocythemia and Polycythemia Vera

Hematol Oncol Clin North Am. 2021 Apr;35(2):295-303. doi: 10.1016/j.hoc.2021.01.003. Epub 2021 Feb 3.

Authors

Ashwin Kishtagari¹, Aaron T Gerds²

Affiliations

¹ Leukemia & Myeloid Disorders Program, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, CA60, Cleveland, OH 44120, USA.
² Leukemia & Myeloid Disorders Program, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, CA60, Cleveland, OH 44120, USA. Electronic address: gerdsa@ccf.org.

PMID: 33641870
DOI: 10.1016/j.hoc.2021.01.003

Abstract

Consensus guidelines have helped to standardize the care of patients with essential thrombocythemia and polycythemia vera, focusing on reducing the risk of thrombosis, mitigating symptoms, and avoiding therapies that may accelerate disease progression. However, many unmet needs still exist ranging from the roll of antiplatelet therapy in ET to medications that reduce disease progression. Retrospective studies suggest an improvement in myelofibrosis-free survival for treatment with interferons; new agents are looking to also enact disease modification.

Keywords: Bomedemstat; ET; Givinostat; IFN-α; Idasanutlin; MPN; Myeloproliferative neoplasms; PV.

Publication types

Review

MeSH terms

Disease Progression
Humans
Polycythemia Vera* / diagnosis
Polycythemia Vera* / drug therapy
Primary Myelofibrosis* / drug therapy
Retrospective Studies
Thrombocythemia, Essential* / drug therapy